Pro-Dex, Inc.

NASDAQ:PDEX

Medical - Instruments & Supplies

Healthcare
$63.94 +5.86%

+$3.54 today

Market cap
$204.61M
Beta
-0.00
P/E (TTM)
17.1
EPS (TTM)
$3.75
52W Low $23.47High $68.99

Volume 0.04M

Average 0.04M

PDEX Operating Cash Flow

Cash generated by the company's core business operations during the period.

Pro-Dex, Inc.NASDAQ: PDEX

Operating Cash Flow · Q3 FY2026 · quarter ended Mar 2026

Operating cash flow grows, but more slowly than its trailing trend

Q3 FY2026 operating cash flow of $1.63M rose 116.6% year over year, behind the +1601.4% change in trailing-twelve-month operating cash flow. Sequentially, it fell 54.3% from the prior quarter. Over 3 fiscal years it compounded at +25.7% a year.

Context

  • Operating cash flow amounted to 2.5% of revenue in FY2025, down 9.0 pp from a year earlier.
  • Operating cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +116.6% toward the trailing-twelve-month pace of +1601.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.63M-54.3% QoQ
Last fiscal yearJun 2025
-$1.68M-127.1% YoY
LTMMar 2026
$7.34M+1601.4% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+116.6%——
1 year-127.1%——
3-year CAGR+25.7%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(1.68M) USD
Year-over-year change
-127.1%

Operating Cash Flow vs competitors

How PDEX compares with its peers on the latest reported figures

  • PDEX's LTM Mar 2026 operating cash flow of $7.34M is the smallest of the 9 companies compared; the peer median is $18.6M.
  • Its year-over-year change of +1601.4% is the highest of 9, against a peer median of +2.6%.
  • Operating cash flow amounts to 9.8% of revenue for PDEX, versus a peer median of 2583.9%.
PDEX Competitors Peer median
Operating Cash Flow for PDEX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LUCDLucid Diagnostics Inc.LTM Mar 2026$46.12M +4.8%+16.1%898.3%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$36.18M -4.0%-19.0%105.2%
SERASera Prognostics, Inc.LTM Mar 2026$26.84M +0.4%-9.5%47094.7%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$20.25M -34.9%+9.9%—
STSSSkyAI, Inc.LTM Mar 2026$16.95M +126.2%+37.5%4269.4%
MBOTMicrobot Medical Inc.LTM Mar 2026$15.23M +64.0%+4.1%14500.0%
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$12.78M +74.6%+16.9%—
APYXApyx Medical CorporationLTM Mar 2026$7.87M -36.6%-26.7%14.1%
PDEXPro-Dex, Inc.LTM Mar 2026$7.34M +1601.4%+25.7%9.8%
Peer median (excluding PDEX) $18.6M+2.6%+7.0%2583.9%

Competitors are the stored peer set for PDEX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income4.57M4.57M7.07M2.13M8.98M
Depreciation & Amortization726K726K857K1.16M1.24M
Deferred Income Tax(63K)(63K)264K(1.56M)140K
Stock-Based Compensation1.28M1.28M766K605K555K
Change in Working Capital(6.54M)(6.54M)396K(225K)(10.45M)
Accounts Receivables(4.45M)(4.45M)5.43M(3.94M)(2.55M)
Inventory(4.24M)(4.24M)(3.49M)898K(6.94M)
Accounts Payables1.99M1.99M(1.15M)2.44M179K
Other Working Capital162K162K(394K)376K(1.14M)
Other Non-Cash Items(820K)(820K)(3.9M)4.1M(2.14M)
Operating Cash Flow(847K)(847K)5.46M6.2M(1.68M)
Capital Expenditures(1.67M)(1.67M)(974K)(983K)(1.25M)
Acquisitions (Net)00000
Purchases of Investments(334K)(334K)0(1.25M)0
Sales of Investments770K770K89K01.31M
Other Investing Activities(33K)(33K)00(304K)
Investing Cash Flow(1.24M)(1.24M)(885K)(2.23M)(238K)
Debt Repayment8.79M756K(809K)(816K)3.48M
Common Stock Issued96K00042K
Common Stock Repurchased(5.54M)(1.61M)(1.55M)(3.51M)(3.5M)
Dividends Paid00000
Other Financing Activities(4.14M)60K(134K)50K(305K)
Financing Cash Flow(790K)(790K)(2.49M)(4.27M)(292K)
Effect of Forex Changes00000
Net Change in Cash(2.87M)(2.87M)2.09M(305K)(2.21M)
Free Cash Flow(2.52M)(2.52M)4.49M5.22M(2.93M)

Pro-Dex, Inc.

NASDAQ:PDEX

Intrinsic Alpha fair value

Locked

Current Price

$63.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.